N-benzyl-(4-methylpyrimidin-2-yl)amine | 25710-14-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-(4-methylpyrimidin-2-yl)amine
• 英文别名: benzyl-(4-methyl-pyrimidin-2-yl)-amine；N-benzyl-4-methylpyrimidin-2-amine
• CAS: 25710-14-9
• 化学式: C₁₂H₁₃N₃
• mdl: MFCD00452900
• 分子量: 199.255
• InChiKey: CZMJRTJCTRBBQN-UHFFFAOYSA-N

物化性质

• 熔点：
  75-77 °C
• 沸点：
  377.6±45.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-benzyl-(4-methylpyrimidin-2-yl)amine 在 sodium amide 、 甲苯 作用下， 生成 N'-benzyl-N,N-dimethyl-N'-(4-methyl-pyrimidin-2-yl)-ethane-1,2-diamine
  参考文献：
  名称：

  DE823598

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯-4-甲基嘧啶 在 potassium carbonate 作用下， 生成 N-benzyl-(4-methylpyrimidin-2-yl)amine
  参考文献：
  名称：

  Matsukawa; Sirakawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1313

  摘要：

  DOI：

文献信息

• Deaminative Olefination of Methyl <i>N</i>-Heteroarenes by an Amine Oxidase Inspired Catalyst
  作者：Pradip Ramdas Thorve、Biplab Maji

  DOI：10.1021/acs.orglett.0c04060

  日期：2021.1.15

  We explored the bioinspired o-quinone cofactor catalyzed aerobic primary amine dehydrogenation for a cascade olefination reaction with nine different methyl N-heteroarenes, including pyrimidines, pyrazines, pyridines, quinolines, quinoxolines, benzimidazoles, benzoxazoles, benzthiazoles, and triazines. An o-quinone catalyst phd (1,10-phenanthroline-5,6-dione) combined with a Brønsted acid catalyzed

  我们探索了仿生邻醌辅因子催化的有氧伯胺脱氢与九种不同的甲基N-杂芳烃的级联烯化反应，包括嘧啶、吡嗪、吡啶、喹啉、喹啉、苯并咪唑、苯并恶唑、苯并噻唑。一个ø与布朗斯台德酸组合的-quinone催化剂博士（1,10-菲咯啉-5,6-二酮）催化的反应。N-杂芳基芪类化合物在温和条件下以高产率和 ( E )-选择性合成，使用氧气 (1 atm) 作为唯一氧化剂，无需过渡金属盐、配体、化学计量碱或氧化剂。
• Manganese-Catalyzed Direct Olefination of Methyl-Substituted Heteroarenes with Primary Alcohols
  作者：Milan K. Barman、Satyadeep Waiba、Biplab Maji

  DOI：10.1002/anie.201804729

  日期：2018.7.16

  Herein, we present the first catalytic direct olefination of methyl‐substituted heteroarenes with primary alcohols through an acceptorless dehydrogenative coupling. The reaction is catalyzed by a complex of the earth‐abundant transition metal manganese that is stabilized by a bench‐stable NNN pincer ligand derived from 2‐hydrazinylpyridine. The reaction is environmentally benign, producing only hydrogen

  在本文中，我们介绍了通过无受体脱氢偶联与伯醇进行的甲基取代杂芳烃的首次催化直接烯烃化反应。该反应由富含地球的过渡金属锰的复合物催化，该复合物由衍生自2-肼基吡啶的稳定的NNN钳形配体稳定。该反应对环境无害，仅产生氢和水作为副产物。高效地选择性获得了大量的E-二取代烯烃。
• PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Hauze Diane Barbara

  公开号：US20090048282A1

  公开（公告）日：2009-02-19

  The present invention relates to pyrimidine sulfonamide analogs, methods of making pyrimidine sulfonamide analogs, compositions comprising a pyrimidine sulfonamide analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a pyrimidine sulfonamide analog.

  本发明涉及嘧啶磺胺类似物，制备嘧啶磺胺类似物的方法，包含嘧啶磺胺类似物的组合物，以及治疗与经典Wnt-β-连环蛋白细胞信使系统相关的疾病的方法，包括向需要的受试者施用有效量的嘧啶磺胺类似物。
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Linders Joannes Theodorus Maria

  公开号：US20110112111A1

  公开（公告）日：2011-05-12

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.

  本发明涉及一种DGAT抑制剂和过氧化物酶体增殖激活受体（PPAR）激动剂或其前药的组合物。本发明还涉及制备这种组合物的方法，以及包含该组合物的制药组合物和该组合物作为药物的用途。本发明还涉及新型的DGAT抑制剂。本发明还涉及制备这种化合物的方法，以及包含该化合物的制药组合物和该化合物作为药物的用途。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20140329836A1

  公开（公告）日：2014-11-06

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物：其中R1、R2、G、n、p和q的值如规范所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。